ArticleFrontiers in cardiovascular medicine2026
Clinical relevance of circulating endocan and endoglin in excess body weight-associated endothelial dysfunction.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Endothelial dysfunction is an early and pivotal event in the development of cardiovascular disease and a key mechanism linked to atherosclerotic plaque formation. Endocan and endoglin are emerging cardiometabolic markers and novel endothelial mediators that promote vascular smooth muscle cell proliferation and migration, contributing to intima-media thickening. Objectives: We aimed to assess endocan and soluble endoglin levels in young adults in the United Arab Emirates (UAE) and the associations among hyperglycemia, dyslipidemia, and endothelial dysfunction. Materials and methods: In this cross-sectional case-control study at UAE University, 182 young adults aged 18-22 years were classified as normal body weight (BW) ( Results: Of the 182 participants, 88 (48%) were women, 121 (67%) had excess BW, and the mean (standard deviation) age was 19.96 years (1.79). Compared with the normal body weight group, the excess body weight group had significantly higher SBP, DBP, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor- Conclusions: Among these young adults, elevated endocan and endoglin levels correlated with excess body weight and adverse metabolic profiles. Prospective studies are needed to determine whether these biomarkers predict future cardiometabolic or vascular outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.